Alto Neuroscience (ANRO) Stock Overview
Operates as a clinical-stage biopharmaceutical company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ANRO Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Alto Neuroscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.22 |
| 52 Week High | US$28.44 |
| 52 Week Low | US$2.15 |
| Beta | 1.65 |
| 1 Month Change | -21.87% |
| 3 Month Change | 20.43% |
| 1 Year Change | 600.33% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 2.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| ANRO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.7% | 4.9% | 1.0% |
| 1Y | 600.3% | 44.2% | 28.7% |
Return vs Industry: ANRO exceeded the US Pharmaceuticals industry which returned 41.8% over the past year.
Return vs Market: ANRO exceeded the US Market which returned 27.1% over the past year.
Price Volatility
| ANRO volatility | |
|---|---|
| ANRO Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ANRO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ANRO's weekly volatility has decreased from 18% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 68 | Amit Etkin | www.altoneuroscience.com |
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson’s disease for patients with Parkinson’s disease.
Alto Neuroscience, Inc. Fundamentals Summary
| ANRO fundamental statistics | |
|---|---|
| Market cap | US$755.04m |
| Earnings (TTM) | -US$74.31m |
| Revenue (TTM) | n/a |
Is ANRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANRO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$74.31m |
| Earnings | -US$74.31m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 7.5% |
How did ANRO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 11:11 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alto Neuroscience, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Tazeen Ahmad | BofA Global Research |
| Thomas Shrader | BTIG |